Stanford University
Showing 1,771-1,780 of 2,461 Results
-
Jonathan Pritchard
Bing Professor of Population Studies, Professor of Genetics and Biology
Current Research and Scholarly InterestsWe are interested in a broad range of problems at the interface of genomics and evolutionary biology. One current focus of the lab is in understanding how genetic variation impacts gene regulation and complex traits. We also have long-term interests in using genetic data to learn about population structure, history and adaptation, especially in humans.
FOR UP-TO-DATE DETAILS ON MY LAB AND RESEARCH, PLEASE SEE: http://pritchardlab.stanford.edu -
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.
-
Carla Pugh, MD, PhD
Thomas Krummel Professor
Current Research and Scholarly InterestsThe Technology Enabled Clinical Improvement (T.E.C.I.) Center is a multidisciplinary team of researchers dedicated to the design and implementation of advanced engineering technologies that facilitate data acquisition relating to clinical performance.
-
Elisabetta Viani Puglisi
Associate Professor (Research) of Structural Biology
Current Research and Scholarly InterestsViral infections and subsequent host response depend on multiple RNA-protein interaction. My research focuses on the structural and functional characterization of RNA-protein complexes involved in viral infection. Current research aims to understand how the Human Immunodeficiency Virus (HIV) initiates its replication upon host infection. We use NMR spectroscopy and x-ray crystallography to study the structure of the initiation complex, formed by a host tRNA and HIV genomic RNA, coupled with biochemical and biophysical methods to understand functional properties. The goal of this research is to gain a molecular view of HIV replication initiation, and use this information to develop new therapeutic approaches to combat HIV.
-
Joseph (Jody) Puglisi
Jauch Professor and Professor of Structural Biology
Current Research and Scholarly InterestsThe Puglisi group investigates the role of RNA in cellular processes and disease. We investigate dynamics using single-molecule approaches. Our goal is a unified picture of structure, dynamics and function. We are currently focused on the mechanism and regulation of translation, and the role of RNA in viral infections. A long-term goal is to target processes involving RNA with novel therapeutic strategies.
-
Patrick Lee Purdon
Professor of Anesthesiology, Perioperative and Pain Medicine (Department Research) and, by courtesy, of Bioengineering
BioMy research integrates neuroimaging, biomedical signal processing, and the systems neuroscience of general anesthesia and sedation.
We are a neuroengineering lab focused on brain dynamics, brain health, and the neural mechanisms of anesthesia. Our research aims to understand the brain dynamics of aging, Alzheimer’s disease, child development, sleep, anesthesia, and consciousness. We use this knowledge to develop novel technologies for brain monitoring and physiological control. We also teach anesthesiologists how to use EEG to provide personalized anesthesia care. -
Stanley Qi
Associate Professor of Bioengineering and, by courtesy, of Biomedical Data Science
BioStanley Qi (publishing as Lei S. Qi) is a pioneer in the field of genome engineering and the architect of the foundational technologies that transitioned CRISPR from a "cutting" tool into a universal platform for Programmable Biology. As the inventor of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), Qi established the first methods for the precise, reversible, and targeted regulation of the human genome without altering the DNA sequence.
The Qi Lab integrates scalable genomic perturbation with live-cell and super-resolution imaging and computation-guided design to redefine the boundaries of cellular control. Under Dr. Qi’s leadership, the group has fundamentally expanded the genome engineering toolbox, evolving CRISPR from a single editing tool into a multidimensional platform for the precise control of dynamic and spatial cell states. This work includes establishing foundational technologies and architectures for precise epigenetic editing, multiplexed regulation of the transcriptome, programmable 3D genome organization, and spatial control of RNA logistics. By pioneering real-time visualization of chromatin dynamics and RNA in living cells, the lab provides an unprecedented window into the fundamental "control principles of life."
This principle-driven technology lineage has moved into the clinic, with the lab's compact epigenetic editor currently in first-in-human clinical testing for FSHD muscular dystrophy (NCT06907875). This milestone represents a core mission of the lab: translating foundational engineering into next-generation therapeutics that act predictably as dynamic, complex systems.
Beyond single-cell control, the Qi Lab is building a framework for synthetic cell–cell communication, with a particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors.
By integrating computational design with experimental biology, Dr. Qi aims to identify the generalizable rules linking molecular programs to systems-level physiology. He is a Chan Zuckerberg Biohub Investigator and an Institute Scholar at the Sarafan ChEM-H, and is dedicated to shaping the technical and ethical frameworks that will define the future of human genome engineering.
